<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="555">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153928</url>
  </required_header>
  <id_info>
    <org_study_id>12091984</org_study_id>
    <nct_id>NCT05153928</nct_id>
  </id_info>
  <brief_title>Management of Uterine Leiomyomata and Adenomyosis</brief_title>
  <official_title>Management of Uterine Leiomyomata and Adenomyosis : Role of Hysteroscopy in Diagnosis and Norethisterone in the Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Ali Mahmoud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. to determine the role of hysteroscopy and guided biopsy to differentiate between&#xD;
           submucosal fibroids and adenomyosis confirmed by histopathological examination&#xD;
&#xD;
        2. to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis&#xD;
           and leiomyoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is:&#xD;
&#xD;
        1. to determine the role of hysteroscopy and guided biopsy to differentiate between&#xD;
           submucosal fibroids and adenomyosis confirmed by histopathological examination&#xD;
&#xD;
        2. to evaluate the efficacy of norethisterone in the treatment of symptomatic adenomyosis&#xD;
           and leiomyoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2021</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Actual">November 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>is to evaluate sensitivity and specificity of hysteroscopy in differentiating between uterine adenomyosis and leiomyomatosis</measure>
    <time_frame>6 months</time_frame>
    <description>Symptomatic improvement</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Abnormal Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>fibroid cases</arm_group_label>
    <description>Norethisterone acetate for 5 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adenomyosis</arm_group_label>
    <description>Norethisterone acetate for 5 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethisterone acetate</intervention_name>
    <description>Norethisterone acetate for 5 months</description>
    <arm_group_label>adenomyosis</arm_group_label>
    <arm_group_label>fibroid cases</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Histopathological study&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        single arm single center study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - (1) ageâ‰¥30 years; (4) dysmenorrhea, adenomyosis-associated chronic pain, and/or&#xD;
        menorrhagia.&#xD;
&#xD;
        (3) regular menstrual cycles before administration of norethisterone; (4) no other&#xD;
        treatment for adenomyosis/leiomyomatosis at least for 3 months biopsies and histopathology&#xD;
        for operated patients;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) pregnant and/or breast-feeding women (2) patients with a ovarian neoplasm, benign&#xD;
             ovarian cyst including endometrioma, pelvic inflammatory disease or other endocrine&#xD;
             diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Mo Taleb, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ahmed Al Dr, Msc</last_name>
    <phone>00201003734246</phone>
    <phone_ext>002024745305</phone_ext>
    <email>rcogahmedali@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Ali</last_name>
    <phone>00201003734246</phone>
    <email>Drarmy1984@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ahmed Ali</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maternaty hospital in assiut</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Wilde S, Scott-Barrett S. Radiological appearances of uterine fibroids. Indian J Radiol Imaging. 2009 Jul-Sep;19(3):222-31. doi: 10.4103/0971-3026.54887.</citation>
    <PMID>19881092</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Ali Mahmoud</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

